Clinicopathologic Significance of Survivin Expression in Relation to CD133 Expression in Surgically Resected Stage II or III Colorectal Cancer

Li, Wanlu; Lee, Mi Ra; Choi, Eun Hee; Cho, Mee Yon

doi:10.4132/jptm.2016.09.23

Cited by 20 publications

(16 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumour antigens survivin and MUC1 are both reported to be upregulated and associated with the recurrence, metastasis and drug resistance in many cancers . In our previous research, survivin and MUC1 showed a better antitumour effect when combined in a vaccine than when given separately in a murine melanoma model .…”

Section: Introductionmentioning

confidence: 81%

MUC1‐ and Survivin‐based DNA Vaccine Combining Immunoadjuvants CpG and interleukin‐2 in a Bicistronic Expression Plasmid Generates Specific Immune Responses and Antitumour Effects in a Murine Colorectal Carcinoma Model

et al. 2018

View full text Add to dashboard Cite

DNA vaccination is a promising cancer treatment due to its safety, but poor immunogenicity limits its application. However, immunoadjuvants, heterogeneous prime-boost strategies and combination with conventional treatments can be used to improve the antitumour immune effects. A CpG motif and interleukin-2 (IL-2) cytokine are often used as adjuvants. In this study, a DNA vaccine containing a CpG motif was constructed to evaluate its adjuvant effect. The results show that the cytotoxicity of the DNA vaccine was increased fivefold, and survival lifetime was prolonged twofold by the CpG motif adjuvant. To simplify the industrial production process, a bicistronic plasmid was constructed to carry the fusion genes of survivin/MUC1 (MS) and IL-2 and with a CpG motif in its backbone. The results showed that the antitumour effect of the bicistronic vaccine was the same as that of the two vaccine co-injected regime. Furthermore, the vaccine could suppress metastatic tumour foci by 69.1% in colorectal carcinoma-bearing mice. Moreover, the vaccine induced survivin- and MUC1-specific immune responses in splenocytes and induced the immune promoting factor CCL-19 and GM-CSF upregulated, while metastatic-associated factor MMP-9 and immunosuppressing factor PD-L1 downregulated in tumour tissue. When combining the vaccine with the chemotherapy drug oxaliplatin, the survival was prolonged by about 2.5-fold. In conclusion, the DNA vaccine containing a CpG motif in bicistronic form showed good effects on colorectal cancer by inhibiting both tumour growth and metastasis, and combination with oxaliplatin could improve its antitumour effects.

show abstract

Section: Introductionmentioning

confidence: 81%

MUC1‐ and Survivin‐based DNA Vaccine Combining Immunoadjuvants CpG and interleukin‐2 in a Bicistronic Expression Plasmid Generates Specific Immune Responses and Antitumour Effects in a Murine Colorectal Carcinoma Model

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Experiments in vitro indicate that survivin can inhibit cell apoptosis by directly or indirectly interfering with caspase function (22). Direct action of survivin on caspases mainly represents the process of caspase-3 and -7 activity suppression and cell apoptosis blocking (22). Moreover, survivin indirectly inhibits caspase through P21.…”

Section: Discussionmentioning

confidence: 99%

Upregulation of miR-542-3p inhibits the growth and invasion of human colon cancer cells through PI3K/AKT/survivin signaling

et al. 2017

View full text Add to dashboard Cite

The present study was designed to assess the expression of microRNA-542-3p (miR-542-3p) in human colon cancer and investigate the possible molecular mechanisms underlying the effect of miR-542-3p on the growth and invasion of colon cancer cells. We found that miR-542-3p expression was downregulated in colon cancer patient tissues, compared with that observed in the control group. Silencing of miR‑542-3p expression significantly promoted cell viability and inhibited apoptosis. In addition, overexpression of miR-542-3p significantly reduced cell viability and promoted apoptosis in colon cancer cells. Meanwhile, silencing of miR-542-3p expression significantly suppressed PI3K and p-AKT and survivin protein expression, while overexpression of miR-542-3p significantly induced PI3K and p-AKT and survivin protein expression in colon cancer cells. PI3K inhibitor (LY294002) or survivin inhibitor (YM155) suppressed PI3K/AKT/survivin signaling and increased the anticancer effects of miR-542-3p on the apoptosis in colon cancer. The present study demonstrated that upregulation of miR-542-3p inhibited the growth and invasion of colon cancer cells through PI3K/AKT/survivin signaling, highlighting a novel therapeutic approach for the treatment of colon cancer.

show abstract

“…The elevated expression of BIRC5 induced by activation of the CXCL12/ CXCR4 signaling pathway in cells exposed to radiation may be a crucial factor for the acquisition of chemoresistance in this cancer type (Wang et al, 2017a). However, no association was found between expression of BIRC5 and invasion, lymph node metastasis, nor histologic differentiation (Li et al, 2017). Survivin depletion by the EpCAM-aptamer-guided BIRC5 RNAi enhanced colorectal cancer stem cells sensitivity to 5-FU and oxaliplatin, further inducing apoptosis, reducing tumor growth and improving the overall survival in a colorectal cancer xenograft model (AlShamaileh et al, 2017).…”

Section: Colorectal Cancermentioning

confidence: 99%

BIRC5 (baculoviral IAP repeat containing 5)

Branco¹,

Jimenez²,

Machado-Neto³

et al. 2019

Atlas of Genetics and Cytogenetics in Oncology and Haematology

View full text Add to dashboard Cite

BIRC5, also known as survivin, has been implicated in cell cycle progression and apoptosis avoidance. BIRC5 is highly expressed in embryonic tissues, however very low or absent in adult tissues. BIRC5 overexpression has been frequently associated to cancer development, a poor prognosis and chemoresistance. Besides that, different BIRC5 isoforms has been characterized and related to better or worse chemotherapy responses depending on the isoform and the cancer type. So far, many efforts have been conducted in order to deplete BIRC5 in cancer cells, including gene therapy, pharmacological and nanotechnological approaches. In this review, we will discuss the role of BIRC5 in cancer cell biology and its clinical significance, demonstrating its DNA/RNA and protein aspects, also its relevance for diagnosis and prognosis, and advances as a target for the treatment of different cancer types.

show abstract

Clinicopathologic Significance of Survivin Expression in Relation to CD133 Expression in Surgically Resected Stage II or III Colorectal Cancer

Cited by 20 publications

References 26 publications

MUC1‐ and Survivin‐based DNA Vaccine Combining Immunoadjuvants CpG and interleukin‐2 in a Bicistronic Expression Plasmid Generates Specific Immune Responses and Antitumour Effects in a Murine Colorectal Carcinoma Model

MUC1‐ and Survivin‐based DNA Vaccine Combining Immunoadjuvants CpG and interleukin‐2 in a Bicistronic Expression Plasmid Generates Specific Immune Responses and Antitumour Effects in a Murine Colorectal Carcinoma Model

Upregulation of miR-542-3p inhibits the growth and invasion of human colon cancer cells through PI3K/AKT/survivin signaling

BIRC5 (baculoviral IAP repeat containing 5)

Contact Info

Product

Resources

About